Abstract
The parasite Plasmodium vivax is the most widely distributed cause of recurring malaria. N-Myristoyltransferase (NMT), an enzyme that catalyses the covalent attachment of myristate to the N-terminal glycine of substrate proteins, has been described as a potential target for the treatment of this disease. Herein, we report the synthesis and the structure-guided optimization of a series of quinolines with balanced activity against both Plasmodium vivax and Plasmodium falciparum N-myristoyltransferase (NMT).
Original language | English |
---|---|
Pages (from-to) | 191-197 |
Number of pages | 7 |
Journal | MedChemComm |
Volume | 8 |
Issue number | 1 |
Early online date | 11 Nov 2016 |
DOIs | |
Publication status | Published - 2017 |